Medical Metrics

Medical Metrics

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Medical Metrics is a specialized imaging core lab and CRO that has been a key partner in over 50 pivotal regulatory approvals, serving clients from startups to multinational corporations. The company leverages a 'Science First' approach, employing staff with advanced biomedical degrees and recognized physician experts to design and execute imaging strategies for clinical trials. Its expertise covers a broad range of therapeutic areas including spine, orthopedics, cardiovascular, neurology, oncology, and AI-driven imaging research, positioning it as a trusted, full-service provider in the clinical trial imaging ecosystem.

SpineOrthopedicsCardiovascularENTNeurologyGastrointestinal & UrologyOncology

Technology Platform

Integrated service platform combining scientific expertise, ISO 9001:2015-certified operational processes, and imaging informatics for centralized trial image analysis. Employs a 'Science First' approach with capabilities in standard imaging modalities and AI-driven analytics.

Opportunities

Growth is driven by the increasing reliance on imaging biomarkers in clinical trials, particularly in oncology and complex device studies.
Expansion into AI-augmented image analysis and specialized software platforms (e.g., SpineCAMP™) offers new service lines and efficiency gains.

Risk Factors

Revenue is tied to the volatile clinical trial spending cycle.
The company faces competition from both large CROs and niche imaging labs.
Technological disruption and evolving regulatory standards for imaging endpoints require continuous adaptation and investment.

Competitive Landscape

MMI competes in the specialized imaging CRO market against other pure-play imaging labs (e.g., BioClinica, now part of Labcorp, ICON plc's imaging services) and the imaging divisions of large, full-service CROs. Its differentiation is based on deep therapeutic expertise, a 'Science First' consulting approach, and a strong track record in regulatory submissions.